Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Genflow Biosciences PLC - London-based biotechnology company - Enters into a collaborative research agreement with Organips, a French biotechnology company. The collaboration will research the potential of the Sirtuin-6 gene variant found in people aged 100 and over in reserving the ageing process in cells from patients with Werner syndrome. Werner syndrome is a rare condition characterised by premature ageing.
Chief Executive Eric Leire says: ‘Through this collaboration, Genflow will work on reprogramming cells from patients with Werner Syndrome with the aim of taking the prematurely aged cells from Werner patients and making them young again. Reprograming is one of the most exciting research areas within the longevity field and is attracting significant investment.’
Current stock price: 8.26 pence, down 8.2%
12-month change: down 28%
Copyright 2022 Alliance News Limited. All Rights Reserved.